Zelluna ASA Completes Significant Share Structure Adjustment
Zelluna ASA, a pioneering company in the biotech industry, has successfully registered a reverse share split with a 10 to 1 ratio. This achievement marks a critical milestone for the company, which focuses on advancing innovative treatments for cancer.
Details of the Share Split
The reverse share split is now officially recorded with the Norwegian Register of Business Enterprises. As a result, the total number of outstanding shares in Zelluna ASA is now 20,227,066, with each share having a par value of NOK 1. This strategic move is designed to streamline the company’s share structure, potentially enhancing the accessibility and attractiveness of their stock to investors.
Leadership Insights on the Transformation
Hans Vassgård Eid, the Chief Financial Officer of Zelluna ASA, emphasized the importance of this move for the company's future. “This consolidation empowers us to pursue complex strategies in the market, aligning with our long-term vision. We believe this shift will offer more opportunities for growth and investment,” he stated.
Company Mission and Innovations
Zelluna's core mission revolves around delivering groundbreaking therapies capable of curing advanced solid cancers efficiently and safely. Leveraging the immune system’s most powerful components, Zelluna is focused on developing "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies. With this innovative approach, they aim to address the complexity and diversity of cancer.
Upcoming Projects
One of Zelluna's notable projects is the world’s first MAGE-A4 targeting “off the shelf” TCR-NK therapy, which promises to be a game-changer in the treatment of solid cancers. In addition to this flagship initiative, a robust pipeline of therapies is in development to broaden their impact in the oncology space.
Strategic Vision for Future Growth
Looking ahead, Zelluna ASA is positioned to make significant strides in cancer therapy. The management team, comprised of seasoned biotech entrepreneurs, is dedicated to advancing from discovery to clinical development, ensuring that innovative cell-based therapies are brought to market. This strategic direction reflects their commitment to overcoming the challenges in current cancer treatments.
Contact Information
For additional queries or more information about Zelluna ASA, you can reach out to:
Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632
Frequently Asked Questions
What is the purpose of the reverse share split at Zelluna ASA?
The reverse share split aims to enhance the company’s share structure, making it more attractive to potential investors.
How will the reverse share split affect the current shareholders?
Shareholders will see their total number of shares decrease by a factor of 10 while maintaining equivalent ownership value.
What innovations is Zelluna ASA working on?
Zelluna is focused on developing advanced TCR-NK cell therapies targeting solid cancers, with multiple therapies in the pipeline.
Who can shareholders contact for more information?
Shareholders can contact Hans Vassgård Eid, the CFO, for any queries or additional information.
What does "off the shelf" therapy mean?
“Off the shelf” therapies refer to ready-made treatments that can be used immediately, without the need for customization for each individual patient.
